SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract

MT Newswires Live

2025/05/23

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody (mAb), a Friday Hong Kong bourse filing said.

The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.

The biopharmaceutical firm and HBM (HKG:2142) in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537133891"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537133891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537133891?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537133891","market":"sh","top_or_hot":-1,"title":"SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody (mAb), a Friday Hong Kong bourse filing said.</p><p>The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.</p><p>The biopharmaceutical firm and HBM (HKG:2142) in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-23 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody (mAb), a Friday Hong Kong bourse filing said.</p><p>The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.</p><p>The biopharmaceutical firm and HBM (HKG:2142) in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科倫博泰生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537133891","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537133891","pubTimestamp":1747998001,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody , a Friday Hong Kong bourse filing said.The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.The biopharmaceutical firm and HBM  in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物-B","02142":"和铂医药-B","BK1161":"生物科技","BK1574":"生物医药B类股","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1583":"高瓴概念"},"translate_title":"SKB生物制药根据药品许可合同获得预付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9,"02142":0.9},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody (mAb), a Friday Hong Kong bourse filing said.The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.The biopharmaceutical firm and HBM (HKG:2142) in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}